The Pancreatic Cancer Action Network is aiming to improve the lives of patients diagnosed with the third-leading cause of cancer-related death with a new precision drug trial.
Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.
For the first time, researchers suggest that underlying genetic mutations may cause pancreatic adenocarcinoma tumors to stiffen up and produce a dangerous thickening and scarring of the tissue around them.
Neutralizing intratumoral pH may help improve responses to immunotherapy and improve outcomes with current targeted therapies, according to a study published March 15, 2016, in the journal Cancer Research.
An integrated genomic analysis has found that pancreatic cancer can be divided into four specific subtypes based on molecular characteristics. This division could help guide treatment decisions and future research avenues into this difficult malignancy.
A new study is suggesting that cancer drugs known as CDK4/6 inhibitors alter the metabolism of pancreatic cancer cells, leaving these cells to be more vulnerable to targeted agents.
Testing for BRCA gene mutations has become a mainstay for patients with breast cancer and their first-degree relatives. There may also be a connection between BRCA mutation carriers and those with pancreatic cancer.
Researchers have sequenced 100 pancreatic ductal adenocarcinomas (PDACs) from patients, identifying four subtypes with distinct clinical features.
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.
Priming pancreatic ductal adenocarcinoma (PDAC) with a combination of a vaccine and low-dose chemotherapy before surgery resulted in an immune response, including an increase in immune cells that express key immunogenic proteins within pa